Bristol Myers Squibb (CELG-RI) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -92.23% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.33% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 65.85% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -635.24% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -108.13% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -69.68% |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 152.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 152.55% |
| Mar 31, 2026 | 8.81% |
| Dec 31, 2025 | 1,328.95% |
| Sep 30, 2025 | 80.66% |
| Jun 30, 2025 | -22.03% |
| Mar 31, 2025 | 120.68% |
| Dec 31, 2024 | -95.69% |
| Sep 30, 2024 | -37.18% |
| Jun 30, 2024 | -18.92% |
| Mar 31, 2024 | -625.28% |
| Dec 31, 2023 | -12.99% |
| Sep 30, 2023 | 20.27% |
| Jun 30, 2023 | 45.35% |
| Mar 31, 2023 | 76.70% |
| Dec 31, 2022 | -14.63% |
| Sep 30, 2022 | 3.61% |
| Jun 30, 2022 | 34.68% |
| Mar 31, 2022 | -36.77% |
| Dec 31, 2021 | 123.66% |
| Sep 30, 2021 | -17.36% |